Aminoglutethimide bioavailability, pharmacokinetics, and binding to blood constituents

The bioavailability of aminoglutethimide tablets was examined using a spectrophotometric assay. For six subjects receiving 500 mg of aminoglutethimide as an oral solution, the average peak concentration was 6.2 μg/ml with a median time of 0.8 hr. The corresponding average peak concentration for tablet administration was 5.9 μg/ml with a median time of 1.5 hr. Average values for the area under the curve (AUC) extrapolated to infinity were 89.0 and 96.8 μg hr/ml for the solution and tablets, respectively. The tablets had a 9% larger mean for the AUC than the solution and a 5% lower value for the mean maximum concentration. The bioavailability of the tablets is considered equal to that of oral solution. Data for individual concentration versus time curves were treated by nonlinear least-squares curve fitting. A two-compartment model with first-order absorption gave an acceptable fit for most data sets, but the individual absorption rate coefficients were not reliably determined. Values were estimated for plasma clearance, renal clearance, and volume of distribution. The distribution of aminoglutethimide between plasma and cells of human blood was examined in vitro; the drug concentration in cells was 1.4-1.7 times the concentration in plasma. The binding of aminoglutethimide to plasma proteins of human blood was measured by equilibrium dialysis at starting concentrations of 5 and 10 μg/ml. The binding ranged from 21.3 to 25.0% without concentration dependence.